Literature DB >> 20416964

Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy - relation to prognosis and liver function.

Hiroshi Imada1, Hirotoshi Kato, Shigeo Yasuda, Shigeru Yamada, Takeshi Yanagi, Ryusuke Hara, Riwa Kishimoto, Susumu Kandatsu, Shinichi Minohara, Jun-etsu Mizoe, Tadashi Kamada, Osamu Yokosuka, Hirohiko Tsujii.   

Abstract

BACKGROUND AND
PURPOSE: To examine whether liver volume changes affect prognosis and hepatic function in patients treated with carbon ion radiotherapy (CIRT) for hepatocellular carcinoma (HCC).
MATERIAL AND METHODS: Between April 1995 and March 2003, among the cases treated with CIRT, 43 patients with HCC limited to the right hepatic lobe were considered eligible for the study. The left lateral segment was defined as the non-irradiated region. Liver volume was measured using contrast CT at 0, 3, 6, and 12 months after CIRT. We examined serum albumin, prothrombin activity, and total bilirubin level as hepatic functional reserve.
RESULTS: After CIRT, the non-irradiated region showed significant enlargement, and enlarged volume of this region 3 months after CIRT 50 cm(3) was a prognostic factor. The 5-year overall survival rates were 48.9% in the larger enlargement group (enlarged volume of non-irradiated region 3 months after CIRT > or =50 cm(3)) and 29.4% in the smaller enlargement group (as above, <50 cm(3)). The larger enlargement group showed better hepatic functional reserve than the smaller enlargement group 12 months after CIRT.
CONCLUSIONS: This study suggests that compensatory enlargement in the non-irradiated liver after CIRT contributes to the improvement of prognosis. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20416964     DOI: 10.1016/j.radonc.2010.03.025

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

1.  Current management of patients with hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Sadahisa Ogasawara; Tetsuhiro Chiba; Yuki Haga; Masao Omata; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-07-28

Review 2.  Clinical evidence of particle beam therapy (carbon).

Authors:  Tadashi Kamada
Journal:  Int J Clin Oncol       Date:  2012-03-17       Impact factor: 3.402

3.  Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma.

Authors:  Maiko Yoshida; Hiroyuki Ogino; Hiromitsu Iwata; Yukiko Hattori; Shingo Hashimoto; Koichiro Nakajima; Shigeru Sasaki; Masaki Hara; Yoshitaka Sekido; Jun-Etsu Mizoe; Yuta Shibamoto
Journal:  Oncol Lett       Date:  2019-01-11       Impact factor: 2.967

4.  Implementing Radiation Dose-Volume Liver Response in Biomechanical Deformable Image Registration.

Authors:  Daniel F Polan; Mary Feng; Theodore S Lawrence; Randall K Ten Haken; Kristy K Brock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-06-27       Impact factor: 7.038

5.  Compensatory hypertrophy of the liver after external beam radiotherapy for primary liver cancer.

Authors:  Chai Hong Rim; Sangjoon Park; Joong Yeol Woo; Jinsil Seong
Journal:  Strahlenther Onkol       Date:  2018-08-13       Impact factor: 3.621

6.  The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Shyh-An Yeh; Yaw-Sen Chen; Daw-Shyong Perng
Journal:  J Radiat Res       Date:  2014-11-19       Impact factor: 2.724

7.  Evaluation of Focal Liver Reaction after Proton Beam Therapy for Hepatocellular Carcinoma Examined Using Gd-EOB-DTPA Enhanced Hepatic Magnetic Resonance Imaging.

Authors:  Shigeyuki Takamatsu; Kazutaka Yamamoto; Yoshikazu Maeda; Mariko Kawamura; Satoshi Shibata; Yoshitaka Sato; Kazuki Terashima; Yasuhiro Shimizu; Yuji Tameshige; Makoto Sasaki; Satoko Asahi; Tamaki Kondou; Satoshi Kobayashi; Osamu Matsui; Toshifumi Gabata
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

8.  Metformin enhances the radiosensitivity of human liver cancer cells to γ-rays and carbon ion beams.

Authors:  Eun Ho Kim; Mi-Sook Kim; Yoshiya Furusawa; Akiko Uzawa; Soorim Han; Won-Gyun Jung; Sei Sai
Journal:  Oncotarget       Date:  2016-12-06

9.  Surgical findings and technical knacks to performing living donor liver transplantation for hepatocellular carcinoma recurrence after carbon ion radiotherapy.

Authors:  Yu Huang; Masaaki Hidaka; Mitsuhisa Takatsuki; Akihiko Soyama; Tomohiko Adachi; Shinichiro Ono; Tota Kugiyama; Takanobu Hara; Satomi Okada; Tomoko Yoshimoto; Takashi Hamada; Susumu Eguchi
Journal:  J Surg Case Rep       Date:  2018-08-22

10.  Long-Term Results of High-Dose 2-Fraction Carbon Ion Radiation Therapy for Hepatocellular Carcinoma.

Authors:  Shigeo Yasuda; Hirotoshi Kato; Hiroshi Imada; Yuka Isozaki; Goro Kasuya; Hirokazu Makishima; Hiroshi Tsuji; Daniel K Ebner; Shigeru Yamada; Tadashi Kamada; Hirohiko Tsujii; Naoya Kato; Masaru Miyazaki
Journal:  Adv Radiat Oncol       Date:  2019-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.